LifeCare’s Cutting-Edge Approach: GeSiM Machines Enable Series Production of Chip-based Glucose Sensor:
LifeCare, a forward-thinking medical sensor company, recently published a groundbreaking move towards automated production through a strategic purchase order from GeSiM mbH. This significant step not only demonstrates LifeCare’s commitment to advancing medical sensor technology but also showcases the incredible flexibility and customization capabilities of GeSiM machines in handling complex and non-standard applications.
In the pursuit of developing the next generation Continuous Glucose Monitor (CGM), LifeCare’s decision for automated production aligns with their ambitious roadmap for a product launch in the veterinary market by Q2 2024. Our bioprinter BS 3.3 and micropipetting station NP 2.1 play a pivotal role in the automated process, filling nanosized chambers of sensors and applying nano-porous membranes to seal them.
LifeCare’s choice of our BioScaffolder (BS 3.3) and a customized Nano-Plotter (NP 2.1) showcases the remarkable adaptability of these machines. The press release emphasizes how these two distinct instruments will seamlessly collaborate on a single application, to enable the  assembling of their sensor chips and loading reagents to them. GeSiM machines are proving to be more than just tools; they bridge the gap from research to series production enabling companies like LifeCare to navigate the intricacies of their applications with precision.
As LifeCare stands at the forefront of innovation, the synergy between their vision and GeSiM’s machinery paves the way for  new approaches to fight diabetes, one of the most frequent diseases in developed industrial countries. We are excited to be part of this development and eagerly anticipate the results of the pilot production in Q1 and automated production in Q2 of 2024.
More information on the advancements of this project is available here: https://lifecare.no/
